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mulmonary thromboendarterectomy (PTE) is the definitive
treatment for chronic pulmonary hypertension as the re-
ult of thromboembolic disease. Although pulmonary embo-
ism is one of the more common cardiovascular diseases af-
ecting Americans, PTE remains an uncommon procedure,
rimarily because this form of chronic pulmonary hyperten-
ion remains an underdiagnosed condition. Recently there
as been an increasing awareness of recognizing chronic pul-
onary thromboembolic disease as a cause of severe pulmo-
ary hypertension. Although the disease is estimated to occur
n approximately 1 to 5% of all patients who have previously
eveloped an acute pulmonary embolism, the true preva-
ence is suspected to be much higher. Chronic thromboem-
olic pulmonary hypertension (CTEPH) is characterized by
ntraluminal thrombus organization, fibrotic scar-tissue-like
tenosis, and the ensuing vascular remodeling of unaffected
ulmonary vessels. Pulmonary endarterectomy is an operation
hat is considered curative for thromboembolic pulmonary hy-
ertension. The only other alternative surgical procedure for
reatment of pulmonary hypertension is transplantation.
onsidering the curative nature of PTE, long-term affects of
ransplantation, its strict medical regimen and undesirable
ide effects, as well as scarce donor availability, it is clear that
TE is a superior option to transplantation for this condition.
Patients affected by CTEPH may present with a variety of
ebilitating cardiopulmonary symptoms. Considerable
rogress has been made over the past decade in understand-
ng the etiology, prevalence, natural history, and therapeutic
pproach to chronic thromboembolic pulmonary hyperten-
ion. Acute pulmonary thromboembolism and its chronic
equelae are significant causes of morbidity and mortality in
he United States and the world. However, the chronic dis-
ase process, even when established and symptomatic, is no-
oriously underdiagnosed because of the nonspecific nature
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doi:10.1053/j.optechstcvs.2006.10.002f the two major symptoms, effort dyspnea and fatigue, and
he fact that physical findings may be elusive until right heart
ailure occurs. Calculations extrapolated frommortality rates
nd the random incidence of major thrombotic occlusion of
ulmonary vessels at autopsy support an estimate that more
han 100,000 people in the United States currently suffer
rom pulmonary hypertension that could be relieved by op-
ration.1
Once chronic pulmonary hypertension develops, the
rognosis is poor, and it is worse for those who do not have
ntracardiac shunts. Thus, patients with primary pulmonary
ypertension and those with pulmonary hypertension due to
ulmonary emboli fall into a higher risk category than those
ith Eisenmenger’s syndrome and encounter a higher mor-
ality rate. In fact, once the mean pulmonary pressure in
atients with thromboembolic disease reaches 50 mm Hg or
ore, the 3-year mortality approaches 90%.2 Therefore, de-
pite an improved understanding of pathogenesis, diagnosis,
nd management, pulmonary emboli and the long-term se-
uelae of thromboembolic pulmonary hypertension remain
requent and often fatal disorders.
Pulmonary endarterectomy is a technically demanding op-
ration currently performed in only a few select centers
round the world. Proper patient selection, meticulous sur-
ical technique, and careful postoperative management have
ontributed to the effectiveness of this operation. A true end-
rterectomy (not an embolectomy) of all affected segments of
he lung is essential to clear all affected areas of the pulmo-
ary vasculature. The procedure, when performed at an ex-
erienced center, ameliorates pulmonary hypertension by
mproving lung ventilation–perfusion mismatch, signifi-
antly improving right ventricular dysfunction and tricuspid
egurgitation, limiting retrograde expansion of thromboem-
olic material, and preventing arteriopathic changes in the
emaining patent small pulmonary vessels.
In this article, we describe the surgical procedure as it is
erformed at the University of California San Diego (UCSD)
edical Center. To date, the largest surgical volume of pul-
onary endarterectomy has been performed at our center,
nd it is this experience that forms the basis of this report.
Pulmonary endarterectomy for chronic thromboembolic disease 265Operative Technique
Figure 1 After a median sternotomy is made, the pericardium is incised longitudinally and attached to the wound edges.
Full cardiopulmonary bypass is instituted with high ascending aortic cannulation and two caval cannulae. The heart is
emptied on bypass, and a temporary pulmonary artery vent is placed in themidline of themain pulmonary artery about
1 cm distal to the pulmonary valve. Patient is then cooled to 20°C with the pump oxygenator; surface cooling with both
the head jacket and the cooling blanket is also begun. When ventricular fibrillation occurs, an additional vent is placed
in the left atrium through the right superior pulmonary vein. Initially, it is most convenient for the primary surgeon to
stand on the patient’s left side and perform the endarterectomy on the right side. IVC  inferior vena cava; SVC 
superior vena cava; a  artery.
266 M.M. Madani and S.W. JamiesonFigure 2 The approach to the right pulmonary artery is made medial, not lateral, to the superior vena cava. During the
cooling period, some preliminary dissection can be performed, with full mobilization of the right pulmonary artery
from the ascending aorta. The superior vena cava is also fully mobilized. Once the core temperature has reached 20°C,
an aortic cross-clamp is applied and myocardial protection is provided through a single dose of antegrade cold blood
cardioplegia (1 L). The entire procedure is now performed with a single aortic cross-clamp period with no further
administration of cardioplegic solution. Additional myocardial protection is provided by using a cooling jacket sur-
rounding the heart throughout the remainder of the procedure. Both tourniquets are now secured around the superior
and inferior venae cavae to ensure complete drainage and to avoid any air entry in the venous cannulae during
circulatory arrest. SVC  superior vena cava; a  artery.
Pulmonary endarterectomy for chronic thromboembolic disease 267Figure 3 Amodified cerebellar retractor is then used to expose the pulmonary artery between the aorta and the superior
vena cava. An incision is made in the right pulmonary artery from beneath the ascending aorta out under the superior
vena cava and entering the lower lobe branch of the pulmonary artery just after the takeoff of the middle lobe artery. It
is important that the incision stays in the center of the vessel and continues in the middle of the descending pulmonary
artery into the lower.
Any loose thrombus, if present, is now removed. This is necessary to obtain good visualization. It is most important
to recognize, however, that first, an embolectomy without subsequent endarterectomy is quite ineffective and, second,
that, in most patients with chronic thromboembolic hypertension, direct examination of the pulmonary vascular bed
at operation generally shows no obvious embolic material. If the bronchial circulation is not excessive, the endarter-
ectomy plane can be found during this early dissection. However, although a small amount of dissection can be
performed before the initiation of circulatory arrest, it is unwise to proceed unless perfect visibility is obtained because
the development of a correct plane is essential.
The correct plane appears pearly white, which is smooth and silky in appearance and lies between the intima and
media. A microtome knife is used to develop the endarterectomy plane posteriorly, because any inadvertent egress in
this site could be repaired readily, or simply left alone. Once the plane is correctly developed, the specimen is trimmed
as to leave an area of full thickness next to the incision line for subsequent repair and closure.
268 M.M. Madani and S.W. JamiesonFigure 4 With the modified cerebellar retractor in place and the artery well exposed, the dissection is then carried out.
When blood obscures direct vision of the pulmonary vascular bed, thiopental is administered (500 mg to 1 g) until the
electroencephalogram becomes isoelectric. Circulatory arrest is then initiated, and the patient undergoes exsanguina-
tion. All monitoring lines to the patient are turned off to prevent the aspiration of air. Snares are tightened around the
cannulae in the superior and inferior venae cavae. It is rare that one 20-minute period for each side is exceeded.
The endarterectomy is then performed with an eversion technique. Because the vessel is everted and subsegmental
branches are being worked on, a perforation here will become completely inaccessible and invisible later. The specimen
depicted in this figure is grossly enhanced to demonstrate the surgical technique; in fact, most thromboembolic
specimens are much finer and more distal in the segmental and subsegmental branches. This is why the absolute
visualization in a completely bloodless field provided by circulatory arrest is essential. It is important that each
subsegmental branch is followed and freed individually until it ends in a “tail,” beyond which there is no further
obstruction. Residual material should never be cut free; the entire specimen should “tail off” and come free spontane-
ously.
Pulmonary endarterectomy for chronic thromboembolic disease 269Figure 5 Once the right-sided endarterectomy is completed, circulation is restarted, and the arteriotomy is repaired with
a continuous 6-0 polypropylene suture. The hemostatic nature of this closure is aided by the nature of the initial
dissection, with the full thickness of the pulmonary artery being preserved immediately adjacent to the incision. a 
artery.
270 M.M. Madani and S.W. JamiesonFigure 6 After the completion of the repair of the right arteriotomy, the surgeon moves to the patient’s right side. The
pulmonary vent catheter is withdrawn, and an arteriotomy is made from the site of the pulmonary vent hole laterally
to the pericardial reflection, avoiding entry into the left pleural space. Neither pleural cavity is entered. Care must be
taken to avoid injury to the left phrenic nerve. Additional lateral dissection does not enhance intraluminal visibility,
may endanger the left phrenic nerve, andmakes subsequent repair of the left pulmonary arterymore difficult. The heart
is wrapped within a cooling jacket and retracted using a mesh-like basket retractor shown in the figure. a  artery.
Pulmonary endarterectomy for chronic thromboembolic disease 271Figure 7 The left-sided dissection is virtually analogous in all respects to that accomplished on the right. The main
obstructing material is a thickened scar-like tissue that obstructs each branch distally, and removal of only gross
thrombus visible on initial inspection will be ineffective. The plane of dissection is developed posteriorly, and again the
specimen is trimmed around the edges of the incision for subsequent closure. The duration of circulatory arrest
intervals during the performance of the left-sided dissection is subject to the same restriction as the right. The specimen
is followed in each segmental and subsegmental branch to ensure complete removal of the endarterectomy material.
Whenever possible, the left lower lobe should be dissected circumferentially and the specimen followed distally. The
left main bronchus crosses anteriorly and it is extremely important to have firm grasp of the specimen at this location.
If the specimen breaks, it is particularly difficult to regain exposure of these distal branches. a  artery.
272 M.M. Madani and S.W. JamiesonFigure 8 After completion of the endarterectomy, cardiopulmonary bypass is reinstituted and warming is commenced.
During warming, a 10°C temperature gradient is maintained between the perfusate and body temperature. The rewarming
period generally takes approximately 90 to 120minutes but varies according to the body mass of the patient. When the
left pulmonary arteriotomy has been repaired, the pulmonary artery vent is replaced at the top of the incision. The heart
is retracted upwards and to the left, and a posterior pericardial window is made, between the aorta and the left phrenic
nerve. Alternatively a soft drain can be left behind the heart to drain any developing posterior collection.
If other cardiac procedures are required, such as coronary artery or mitral or aortic valve surgery, these are
conveniently performed during the systemic rewarming period. The most common concomitant procedure is closure
of foramen ovale, followed by coronary bypass surgery. Although tricuspid valve regurgitation is invariable in these
patients and is often severe, tricuspid valve repair is not performed. Right ventricular remodeling occurs within a few
days, with the return of tricuspid competence. At the completion of all associated procedures, myocardial cooling is
discontinued. The left atrial vent is removed, and the vent site is repaired. All air is removed from the heart, and the
aortic cross-clamp is removed.
When the patient has fully rewarmed, cardiopulmonary bypass is discontinued. With a successful endarterectomy,
the cardiac output is generally high, with a low systemic vascular resistance. Temporary atrial and ventricular epicardial
pacing wires are placed. Wound closure is routine and similar to other cardiac procedures.
Pulmonary endarterectomy for chronic thromboembolic disease 273Figure 9 Specimen removed from both lungs during pulmonary endarterectomy. The ruler measures 15 cm. Note that
removal of proximal thromboembolic material without endarterectomy of all the distal branches would leave signifi-
cant disease behind, without any relief in pulmonary pressures or the pulmonary vascular resistance. The above
specimen is characterized as Type I disease. There are four broad types of pulmonary occlusive disease related to
thrombus that can be appreciated. Type I disease (approximately 20% of cases) refers to the situation in which major
vessel clot is present and readily visible on the opening of the pulmonary arteries. In Type II disease (approximately
60% of cases), nomajor vessel thrombus can be appreciated. Type III disease (approximately 20% of cases) presents the
most challenging surgical situation. The disease is very distal and confined to the segmental and subsegmental
branches. No occlusion of vessels can be seen initially. The endarterectomy plane must be carefully and painstakingly
raised in each segmental and subsegmental branch. Type IV disease (see Comments) does not represent primary
thromboembolic pulmonary hypertension and is inoperable. In this entity, there is intrinsic small-vessel disease,
although secondary thrombus may occur as a result of stasis. (Color version of figure is available online at http://
www.us.elsevierhealth.com/optechstcvs.)
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274 M.M. Madani and S.W. Jamiesonomments
ulmonary hypertension caused by chronic pulmonary em-
olism is underrecognized and carries a poor prognosis.
edical therapy for this condition is palliative at best and
nly transiently improves symptoms. Because of the obstruc-
ive nature of this disease, the only curative option is to re-
ove all the obstructive thromboembolic material, by means
f pulmonary endarterectomy. The only therapeutic alterna-
ive to pulmonary endarterectomy is lung transplantation;
owever, we consider this inappropriate use of resources and
n inferior option. The advantages of pulmonary endarterec-
omy include a lower operative mortality (3-month survival
or lung transplantation for pulmonary hypertension 1990 to
001, 72%; for heart–lung transplantation for pulmonary
ypertension, 70%3,4), better long-term survival, and the
voidance of chronic immunosuppressive treatment and al-
ograft rejection. Currently our survival rate for pulmonary
ndarterectomy at UCSD is 95.7% (2005 to 2006), and the
peration can provide sustained clinical benefit. Considering
hese results, clearly pulmonary endarterectomy is the pro-
edure of choice and much more advantageous than lung
ransplantation for curative treatment of this disease. Al-
hough through our efforts more and more centers are rec-
gnizing this procedure as the treatment of choice and are
voiding inappropriate lung transplantation, the main prob-
em remains that the condition itself continues to go unrec-
gnized. The patients are generally misdiagnosed and mis-
reated for many years before they are truly identified as
uffering from chronic thromboembolic pulmonary hyper-
ension.
It is noteworthy to point out that, despite favorable results
n our series of over 2000 pulmonary endarterectomies, we
ave come to realize that a small subset of patients do not
enefit from this operation, as they manifest solely arteriolar-
apillary vasculopathy similar to idiopathic pulmonary arte-
ial hypertension. In general these patients do not have any
hromboembolic disease and in essence were actually misdi-
gnosed; however, they are hard to distinguish from their
ounterpart. The main problem is the distal vasculopathy,
nd as such, they do not benefit from pulmonary endarter-
ctomy. With our growing experience, we are accepting
igher risk patients and some with minimal disease. Our
hilosophy is that as long as there is any evidence of throm-
oembolic material on preoperative studies, the patients are
ccepted for surgery if there are no other contraindications.
he risk factor that characterizes patients with vasculopathys high pulmonary pressures and pulmonary vascular resis-
ance (PVR) without much evidence of thromboembolic ob-
truction on angiogram. Unresolved PVR is a significant risk
actor for postoperative morbidity and mortality. In fact, the
ortality rate is about 25% when the residual PVR after op-
ration remains higher than 500 dyn s cm5, but only 2.7%
hen it was below this level. Further refinements in preop-
rative work-up, including pulmonary waveform analysis,
ulmonary angiography, commuted tomography scanning,
nd magnetic resonance imaging, will help to further distin-
uish these patients from those truly affected by obstructive
isease.5-7
Although pulmonary endarterectomy is technically de-
anding for the surgeon, mainly because it requires careful
issection of the pulmonary artery wall planes and the use of
irculatory arrest; excellent results can be achieved. Improve-
ents in operative technique developed over the last three
ecades allow pulmonary endarterectomy to be offered to
atients with low mortality rate and anticipation of clinical
mprovement. Currently, at our institution, no patient is de-
ied operation based on severity of pulmonary hypertension
r age, as long as there is evidence of thromboembolic dis-
ase. With the earlier and more accurate diagnosis of patients
resenting with thromboembolic pulmonary hypertension
nd more common knowledge that pulmonary endarterec-
omy is a safe and quite an effective operation for this condi-
ion, we anticipate that the utility of this procedure will only
ncrease in the future.
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